Today is Rare Disease Day!

Lupus is a rare disease in Europe, although for those living with it, it doesn’t feel rare at all!

There are estimated to be less than five in 10,000 people in Europe who are living with lupus. Having a rare disease means that most people around you don’t have any idea what you are going through.

 

(Positive aspect of COVID and LOCKDOWN?)

 

Up until a year ago, living with lupus meant for some, living in fear and isolation. Some lupus patients take medication that suppresses their immune system to treat their lupus, but this can make people susceptible to infections. Lupus patients often live with the threat of another bug, another flare, another complication and never know what tomorrow might bring.  But today, there’s a new feeling almost of relief. People with lupus do not feel alone anymore!

 

Living in lockdown, with the threat of COVID-19 just outside the door, has brought up feelings of isolation and of being afraid of an invisible enemy for everyone. And while that is horrible and we wish it would stop as soon as possible for people everywhere, it is what some people with lupus may experience all the time. So today when we go out, masked, gloved, with our bottle of sanitising gel, no-one looks at us weirdly. When we avoid parties, or crowds, … for the first time ever we don’t have to explain or justify our behaviour.

 

Surprisingly, there have been positive aspects of this pandemic: the generalisation of remote working, telemedicine becoming a reality, remote ordering of medicines, more awareness of the effects of chronic diseases because of the awareness around “long covid” effects!  Perhaps you have some other examples?  Let’s make sure we are very clear about how much we appreciate those developments.  As lockdowns end and we push COVID to the back of our minds, let’s not forget the lessons we all learned during this time. Let’s all use this experience as a starting point for an ongoing conversation with your friends, your families, your healthcare workers, with society at large.  Let’s all discuss how to keep those improvements, while working together to end the isolation people with rare diseases often feel.

 

(LUPUS AND COVID VACCINES)

One step to getting out of lockdown is the COVID19 vaccination.  SLEuro (The European Lupus Society is a community of clinicians and researchers interested in SLE and related syndromes) has released a very useful Q&A document on the Covid vaccine for patients with SLE.  You can find it here: https://sleuro.org/sars-cov-2/

 

A lot of lupus patients around Europe have been vaccinated already, but many have not yet been offered a vaccine.  Each country has its own vaccination priority lists. Lupus gives automatic priority in some EU countries, not in others. What is the situation in your country? What are things like for you? Have you been vaccinated? Let us know by commenting under this post on our Facebook page and on Twitter!

 

(LUPUS RARE DISEASE)

Today is Rare Disease day. We should all be aware of two significant actors that help the rare disease community raise their voices in Europe: Orphanet and Eurordis

Orphanet is the portal for rare diseases and orphan drugs, a unique resource, gathering and improving knowledge on rare diseases so as to improve the diagnosis, care and treatment of patients with rare diseases. https://www.orpha.net/

 

EURORDIS is a non-governmental patient-driven alliance of patient organisations representing 956 rare disease patient organisations in 73 countries. https://www.eurordis.org/

Have a quick look on their websites and see what they are fighting for and doing for you!

 

(RARE 2030 RECOMMENDATIONS)

This week, the recommendations from the Rare2030 foresight study were released:

 

http://download2.eurordis.org/rare2030/Rare2030_recommendations.pdf

 

Rare 2030 is a proposal of EU policy recommendations that will bring improved policy and a better future for people living with a rare disease in Europe. This two-year project  was presented to EU Parliament last week with recommendations on the most critical areas needing better policy.

Here you can find information about Rare 2030: https://www.rare2030.eu

 

Please have a look at it and share it widely in your groups and countries. We will need to encourage our EU ministers to support it, so it’s good to learn as much as possible about it.

 

Use Rare Disease Day to start that conversation around you.

 

As they say: “Rare diseases are rare, but rare disease patients are numerous”.[/vc_column_text][/vc_column][/vc_row]

Live Facebook Feed

Comments Box SVG iconsUsed for the like, share, comment, and reaction icons

🦋 EULAR started yesterday!

This year, #EULAR2026 brings together a huge rheumatology community:

📊 5,705 abstracts submitted from 102 countries, a new EULAR record
📊 187 scientific sessions across 15 tracks
📊 More than 350 distinguished speakers from 43 nations

And Lupus Europe is here!

As promised, some of our PAN members are covering lupus-related sessions to bring key messages back to the lupus community.

🧑‍🤝‍🧑 One of yesterday’s highlights was seeing Marina Pietri present our poster on Sex & Lupus co-creation, with Rita Vieira also there representing the Youth Group’s work. The poster shows how young people with lupus worked with a clinician to create a safe, respectful space to talk about sex, intimacy and lupus, topics that are still too often left out of routine care.

A big thank you to Dr Cristiana Sieiro Santos for her support and collaboration in making this work possible.

🎥 If you haven’t watched the webinar yet, visit our YouTube channel and watch it there.

🧠 We also followed a session on fatigue, one of the symptoms people with lupus most often report as difficult to explain, measure and manage. The session looked at when tiredness becomes pathological, how fatigue can be assessed, and why lifestyle advice needs to be realistic and adapted to each person.

💬 Patient-doctor communication was another key topic yesterday. Have you heard about the Lupus Consultation Cards? Inspired by the work of NVLE in collaboration with ERN ReCONNET, they are a simple tool to help people prepare for appointments, organise symptoms and questions, and focus the conversation on what matters most. This is the idea behind our #MakeItCount campaign.

🌍 Dr Daniel Guimarães de Oliveira presented a poster on social determinants of health in lupus care, co-authored with our General Secretary Zoe Karakikla Mitsakou. This work shows how healthcare professionals, Patient Research Partners from Lupus Europe, local patient volunteers and social workers co-designed a practical framework to identify barriers such as financial pressure, health literacy, transport, social support and access to care, and connect them with local solutions.

📱 Digital tools were also part of yesterday’s programme, with discussions on how technology can support self-management, shared decision-making and patient empowerment. For Lupus Europe, this strongly connects with our work on reliable, patient-centred digital information, including #LupusGPT and #EasyLupus.

🔬 We also followed the session “The mitochondria: a new culprit for autoimmune diseases?”. The discussion explored how mitochondrial DNA and RNA may act as danger signals, activating immune pathways such as interferon responses and contributing to inflammation in lupus and other autoimmune diseases.

👏 Kudos to our PAN members and Board members for their great job on this first day of EULAR!

🦋 Stay tuned. Today will be another big day for Lupus Europe at #EULAR2026!

Our Chair, Jeanette Andersen, will speak in the session on non-pharmacological interventions to improve quality of life.

We also have a Meet the EULAR Expert session on “AI as a Partner in Care: Empowering the RMD Community with Information”, focusing on AI tools such as #LupusGPT and #EasyLupus, which will be delivered by Zoe Karakikla Mitsakou.
... See MoreSee Less

Image attachment
Image attachment
Image attachment
Image attachment
Image attachment

☀️ Good morning from beautiful London!

#Eular2026 is here, and so are we‼️

💬 You may already know #lupusgpt. You may have read the paper in The Lancet Rheumatology. You may have tried the tool, shared it with a patient, or recommended it to a colleague.

📊 But there is more. More to do. More lessons learned from two years of building something genuinely patient-led. More to understand about what happens when patients, clinicians, and AI specialists work together from the very first question.

🦋 This week, we will be sharing it all.

#lupusgpt: more than you think. Further than you imagined.
... See MoreSee Less

☀️ Good morning

📅 Tomorrow, the EULAR Congress begins!

🌍 #Eular2026 starts tomorrow, and Lupus Europe will be there!

🦋 We will be representing the patient voice, following the latest research, and sharing key updates with our community throughout the week.

Stay tuned for live updates, session highlights, and much more.

💬 Will you be following the congress? Let us know in the comments!
... See MoreSee Less

📅 Tomorrow, the E

🔴 𝐑𝐞𝐦𝐢𝐬𝐬𝐢𝐨𝐧 𝐝𝐨𝐞𝐬𝐧❜𝐭 𝐚𝐥𝐰𝐚𝐲𝐬 𝐟𝐞𝐞𝐥 𝐥𝐢𝐤𝐞 𝐫𝐞𝐦𝐢𝐬𝐬𝐢𝐨𝐧 🔴

This is one of the most important insights from a new editorial just published in Rheumatology.

📋 The editorial responds to a study analysing five years of data from the Amsterdam SLE cohort. The findings are striking:

🔹 In over half of clinical visits, patients rated their disease as more active than their physicians did.
🔹 Even among visits meeting formal remission criteria, more than 1 in 3 patients still reported significant disease burden.

These discrepancies highlight an important gap between how disease activity is measured clinically and how lupus is experienced by patients in daily life

📊 According to LUPUS EUROPE’s Swiss Knife Survey, patients’ definitions of “disease control” often go far beyond normal blood tests. They include 𝗳𝗿𝗲𝗲𝗱𝗼𝗺 𝗳𝗿𝗼𝗺 𝗳𝗹𝗮𝗿𝗲𝘀, 𝘀𝘁𝗮𝗯𝗹𝗲 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁, 𝗾𝘂𝗮𝗹𝗶𝘁𝘆 𝗼𝗳 𝗹𝗶𝗳𝗲, and the ability 𝗹𝗶𝘃𝗲 𝗮𝘀 𝗻𝗼𝗿𝗺𝗮𝗹𝗹𝘆 𝗮𝘀 𝗽𝗼𝘀𝘀𝗶𝗯𝗹𝗲.

𝗦𝗵𝗮𝗿𝗲 𝘄𝗶𝘁𝗵 𝘂𝘀 𝘄𝗵𝗮𝘁 𝗿𝗲𝗺𝗶𝘀𝘀𝗶𝗼𝗻 𝗺𝗲𝗮𝗻𝘀 𝗳𝗼𝗿 𝘆𝗼𝘂. Let's make it visible.

The editorial, co-authored by Dr Alvaro Gomez from Karolinska Institutet, and Zoe Karakikla-Mitsakou, LUPUS EUROPE General Secretary, points to several possible ways this might be addressed:

✅ Incorporating patient-reported outcomes into treatment target definitions
✅ Using assessment tools that better integrate patient-reported symptoms
✅ Exploring broader target frameworks that better reflect what meaningful disease control may look like for people living with lupus

This reinforces why people with lupus must be involved from the start in shaping how treatment success is defined, measured, and pursued.

💬 Have you ever been told you are in remission but not felt like it?

Share what remission means for you in the comments. Let’s make it visible.

📖 Read the full editorial: doi.org/10.1093/rheumatology/keag259
... See MoreSee Less

LUPUS EUROPE Uniting people with Lupus throughout Europe
Send